Open AccessAdverse effects of biologic anti-inflammatory agents on the respiratory system: A review
Author(s) -
D’Andrea K. Joseph,
Gregory Ronald Tintinger,
James Ker,
Nicolette Pannell
Publication year - 2021
Publication title -
african journal of thoracic and critical care medicine
Language(s) - English
Resource type - Journals
eISSN - 2617-0205
pISSN - 2617-0191
DOI - 10.7196/ajtccm.2021.v27i2.117
Subject(s) - medicine , janus kinase , immunology , adverse effect , tumor necrosis factor alpha , cytokine , inflammation , disease , pharmacology
The therapy of autoimmune rheumatological conditions has undergone significant changes with the introduction of biologic antiinflammatory agents including cytokine antagonists and agents that interfere with the function of T and B cells or those that inhibit intracellular enzymes such as Janus kinase (JAK). Although useful to control inflammation, these agents may be associated with druginduced lung disease, which may be difficult to differentiate from pulmonary disorders caused by the underlying autoimmune diseases. This review aims to provide a description of lung disease, both infectious and non-infectious, that may be induced by the administration of biologic anti-inflammatory agents with emphasis on inhibitors of tumour necrosis factor, interleukin-1, interleukin-6 and JAK.